Why not join CURE today? You already belong!

Good for bioscience in Connecticut. Good for you.

The CURE Calendar

Bioscience ClubhouseCT Presents: Taking the Non-Traditional Path – Exploring Strategic Partnership and Commercialization Opportunities in a Key Emerging Market: India @ The Study at Yale
May 4 @ 4:30 pm – 6:00 pm


India has been known to all biopharma companies as a destination to outsource R&D and manufacturing. However, the rapidly evolving landscape in India has opened doors beyond purely outsourcing for cost arbitrage. The seminar will present various elements of the evolving landscape to discuss the growing Indian opportunity for both young ventures and established companies.

The presentation will touch upon –

  • Factors driving the expanded opportunity including renewed innovation focus in Indian companies, 
  • Availability of dilutive and non-dilutive funding for innovation advancement, 
  • Evolving disease profile and sustainable market growth opportunity driven by increasing disposable income and expanded access to healthcare,

The goal is to present models for young ventures to leverage strategic partnerships to expand and accelerate their commercialization programs. Opportunities for established companies across biopharma and medtech to expand their global footprint and participate in the growing market opportunity in India will be discussed along with case studies.


Pravin R. Chaturvedi, PH.D. Dr. Chaturvedi is a serial entrepreneur and a drug development veteran in the pharmaceutical and biotech community. He is the President & Chief Executive Officer of Boston- and Vancouver-based Pivot Pharmaceuticals, Inc., which recently acquired Boston-based IndUS Pharmaceuticals, which was founded and led by Dr. Chaturvedi until its acquisition. He is also the co-founder of Florida-based Oceanyx Pharmaceuticals. He remains an advisor to San Francisco-based Napo Pharmaceuticals, where he was the President and Chief Scientific Officer. Prior to his tenures at Pivot, IndUS, and Napo, he was the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals, which was acquired by Wyeth (now Pfizer). Dr. Chaturvedi serves on the boards of Pivot, Oceanyx, Sindu Research Laboratories, Cellanyx, Bach Pharma, and two non-profit organizations, FuelEd Schools and PRADAN USA. He has previously served on the boards of Scion Pharmaceuticals, Sindu Pharmaceuticals and TiE Boston. He is an adjunct faculty member at Georgetown Medical School and serves on the advisory boards of several entities including Springboard Enterprises, a non-profit organization promoting women’s entrepreneurship. Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or the development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of several new drugs that are currently marketed by various companies. Prior to his entrepreneurial journey, Dr. Chaturvedi spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation and was in the preclinical group at Alkermes. He started his career in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer). Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.

Pushpa Vijayaraghavan, Vice President – Life Sciences Advisory, Sathguru Inc.
Pushpa leads the life sciences practice of Sathguru, a niche emerging markets focused strategy and innovation advisory firm. Founded in 1985 in India, Sathguru’s expertise includes South Asia focused corporate strategy, M&A and innovation advisory encompassing international innovation access, advancement and commercialization. Sathguru has a team of around 150 professionals across service offerings and has offices in India and USA.

Pushpa advises enterprises, research institutions and venture capitalists on advancing innovation and leveraging opportunities in India and other South Asian countries. Pushpa also leads engagements on market entry and growth strategy, research and product prioritization for emerging markets, strategic partnership opportunities, policy and M&A advisory. Pushpa’s prior experience of about thirteen years includes leading consulting engagements at PwC and Ernst &Young and a short stint in the University of Michigan Technology Transfer Office. She has a bachelor’s degree from Osmania University (India) and an MBA from the Ross School of Business at University of Michigan. Pushpa is an often called upon speaker on Indian and emerging market opportunity in life sciences, serves as an alumni advisor to the India Business Conference at the University of Michigan and has led policy advisory engagements for the World Bank and the Government of India among others. 

alkaAlka Shrikhande, Associate Vice President – Life Sciences Advisory, Sathguru Inc.
Alka Shrikhande is the lead resource in Sathguru’s healthcare practice in US. She advises global clients on innovation advancement opportunities and growth avenues in India and other emerging markets. She also works with several Indian companies on their efforts to access innovation and seek strategic partnerships with global partners.

Ms. Shrikhande is a life sciences professional with more than 20 years of experience in the US pharmaceutical industry. She started her career working on cardiovascular research at the Miles Institute of preclinical pharmacology which was later known as Bayer. At Bayer her work involved research in the area of osteoarthritis in the inflammation group advancing a kinase project into the clinics. She was a Senior Scientist in the neuroscience research unit at Pfizer in Groton, CT for over 12 years, contributing to numerous psychotherapeutic projects. In 2010, Alka started BioLink Consultants which offers strategic consulting and business development support to life science companies. Alka obtained her MSc specializing in Microbiology and MBA from the University of New Haven.

Sponsored by:


Sponsored by:


Investor & Entrepreneur Network Event
May 19 @ 8:30 pm – 11:30 pm

Join the movers and shakers of the investment and entrepreneurial community for CVG’s monthly Investor & Entrepreneur Network Event!

BioHaven Presents: Growing Arvinas – Technology, Investment and Business Development: Three Perspectives @ Anlyan Center at Yale
May 26 @ 4:00 pm – 6:00 pm


Arvinas ( is a pharmaceutical company located in New Haven, CT, founded on platform technology developed by Craig Crews at Yale University and focused on developing novel therapeutics to treat a variety of cancer indications. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation, thus eliminating them from the body.  This strategy of degradation versus protein inhibition holds several advantages, including the potential to target proteins that are not currently druggable using a small molecule approach. In addition to developing its pipeline of wholly-owned molecules, Arvinas is engaged in collaborations with Merck and Genentech. In 2015 Arvinas was selected by FierceBiotech as one of its “Fierce 15” biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.


Susan Froshauer, Ph.D. Dr. Froshauer is President and CEO of CURE and President of CURE Innovations, LLC. She is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.



 Tim Shannon:

Timothy Shannon, MD

Timothy Shannon, MD is the Chairman of the Board of Arvinas and a Venture Partner at Canaan Partners. He also serves on the boards of Aldea Pharmaceuticals,Civitas TherapeuticsCytomX Therapeutics and Novira Therapeutics, Canaan portfolio companies.

Dr. Shannon previously was president and chief executive officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer.  He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group including senior vice president of global medical development.  Prior to his career in industry, Dr. Shannon was assistant professor of the pulmonary and critical care division at Yale University School of Medicine.

Dr. Shannon received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.

Manny Litchman:

Manny Litchman, MD

Manny is the President and CEO of Arvinas Inc.  Previously, he was Senior Vice President and Global Program Head at Novartis Pharmaceuticals for the CTL019 project – a collaboration with the University of Pennsylvania (Penn) involving personalized cell and gene therapy. Manny started his pharmaceutical career in Oncology Clinical Research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he held positions of increasing responsibility in Oncology Development. From 2000 – 2001 he was Senior Equity Analyst at Ursus Capital, a biotechnology hedge fund. He then returned to Novartis, where he was Head of Oncology Business Development & Licensing until execution of the Penn deal in 2012. Manny obtained his BA in German Literature from Princeton University and his MD from Yale University School of Medicine. He completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital / Weill Cornell Medical Center.

Craig Crews:

Craig M. Crews, Ph.DCraig Crews is the Founder and Chief Scientific Advisor of Arvinas as well as the L.B. Cullman Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University.

Dr. Crews’ research focuses on the design/syntheses/evaluation of small molecule regulators of intracellular protein levels and their development as novel therapeutics.  YU101, a novel proteasome inhibitor from his lab served as the lead asset in Proteolix, Inc. (purchased by Onyx in 2009;acquired by Amgen 2013) and became carfilzomib/Kyprolis™, which received FDA approval for relapsed/refractory multiple myeloma in 2012.

Sean Cassidy:

Sean Cassidy, CPASean Cassidy is the Chief Financial Officer of Arvinas.  He has over 20 years experience in the life sciences industry, including: Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents; and Deloitte, one of the big four public accounting firms serving a broad base of clients in the health care space.

Sean is also the Treasurer of the Friends of Yale New Haven Children’s Hospital, a non-profit organization that help improve the health and well-being of pediatric patients and their families.

Mr. Cassidy holds an MBA and BS from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.


2016 BIO International Convention
Jun 6 – Jun 9 all-day

The global event for biotechnology returns to the birthplace of biotech, San Francisco, California. The region continues to grow and advance biomedical innovation while continuing to offer programs and services to support to bring new medical advances to patients. Imagine all of the powerful partnerships when these powerful communities of innovation come together – mark your calendar today!

Visit BIO website for more information:

BioHaven – The Story of Alexion
Jun 9 @ 4:00 pm – 6:00 pm

More information to follow.

Serial Entrepreneur: David Scheer

Biotech Entrepreneur Kevin Rakin:
The Business of Science

A CT Bioscience Entrepreneur’s
Story: Craig M. Crews, Ph.D.


Talent Wanted/Talent Available

> Connecticut BioScience Job Listings
> BioScience Résumés

Click Here

Bioscience ClubhouseCT and Career Ladder Grant

Applications now being accepted. Get the details.
Click Here